The UK National Institute for Health and Care Excellence ( ) has recommended Accord’s Relugolix (Orgovyx), as a treatment for advanced hormone-sensitive prostate cancer in its final draft guidance. The androgen deprivation therapy (ADT) is the first oral treatment of its kind to be endorsed by NICE and could potentially benefit 40,000 individuals. The gold standard of business intelligence.
Other hormone treatments are administered through injections, while Relugolix is an oral tablet, providing patients with the convenience of at-home treatment. Prostate cancer cells need androgen hormones such as testosterone to proliferate. ADT works by reducing these hormone levels, either through medication or surgery, to inhibit the growth of prostate cancer cells.
Relugolix functions by obstructing the production of testosterone in the testes, thereby lowering its levels. ADT has been linked to an increased risk of cardiovascular issues, including heart attacks and heart failure. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form Clinical trials indicate that compared with leuprolide, Relugolix can maintain lower testosterone levels – crucial in .